TABLE 1.

Characteristics Compared by Every 4- and Every 6-Week Ustekinumab Intervals

Characteristics	Ustekinumab Every 4 Weeks (n = 64)	Ustekinumab Every 6 Weeks (n = 55)	P a
Age, mean y	42.2	40.3	0.44
Sex, %			0.27
Female	60.9	50.9
Male	39.1	49.1
Race, %			0.12
Asian	3.1	0.0
Black	0.0	5.5
Hispanic	0.0	1.8
Unknown	0.8	3.6
White	89.1	89.1
Age of IBD diagnosis, mean, y	25.0	26.5	0.55
Disease duration at ustekinumab start, mean, y	15.5	12.7	0.08
Time on ustekinumab before intensification, mean, d	363.8	368.7	0.92
Ustekinumab level before intensification, mean, ug/mL, n = 14, n = 4	2.0	1.3	0.54
Current smoking, %	4.7	18.2	0.02
Current cannabis, %	15.6	29.1	0.08
Current opioids, %	35.9	27.3	0.31
HBI within 3 months before intensification %, n = 60			0.66
Remission (<5)	31.7	30.8
Mild (5–7)	23.3	30.8
Moderate (8–16)	43.3	34.6
Severe (>16)	1.7	3.9
Extraintestinal manifestations, %	54.7	47.3	0.42
Prior IBD surgery, %	64.1	63.6	0.96
Prior anti-TNF, %	100.0	100.0	n/a
>1 prior anti-TNF, %	81.3	67.3	0.08
Prior anti-integrin, %	48.4	47.3	0.90
Current corticosteroids, %	31.3	14.6	0.03
CD Location (Montreal classification), %			0.32
L1 Terminal ileum	10.9	16.4
L2 Colon	18.8	25.5
L3 Ileocolon	67.2	56.4
L4 Upper GI	0.0	1.8
L3+L4 Ileocolon + Upper GI	3.1	0.0
CD Behavior (Montreal classification), %			0.36
B1 Nonstricturing, nonpenetrating	21.9	32.7
B2 Stricturing	17.2	18.2
B3 Penetrating	60.9	49.1
Perianal disease, %	37.5	47.3	0.28
Lab markers within 3 months before intensification
Fecal calprotectin >120 mcg/g, %, n = 25; n = 7	88.0	100.0	0.34
Albumin to CRP ratio, mean, n = 54, n = 46	82.3	237.6	0.08

^a Calculated by Student t test or Pearson χ ² test